<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
<journal-title-group>
<journal-title>Scientific Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-2322</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28623346</article-id>
<article-id pub-id-type="pmc">5473876</article-id>
<article-id pub-id-type="publisher-id">2434</article-id>
<article-id pub-id-type="doi">10.1038/s41598-017-02434-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Early-onset primary antibody deficiency resembling common variable immunodeficiency challenges the diagnosis of Wiedeman-Steiner and Roifman syndromes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bogaert</surname>
<given-names>Delfien J.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0223-230X</contrib-id>
<name>
<surname>Dullaers</surname>
<given-names>Melissa</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuehn</surname>
<given-names>Hye Sun</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leroy</surname>
<given-names>Bart P.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niemela</surname>
<given-names>Julie E.</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Wilde</surname>
<given-names>Hans</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Schryver</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Bruyne</surname>
<given-names>Marieke</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coppieters</surname>
<given-names>Frauke</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lambrecht</surname>
<given-names>Bart N.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Baets</surname>
<given-names>Frans</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenzweig</surname>
<given-names>Sergio D.</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>De Baere</surname>
<given-names>Elfride</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Haerynck</surname>
<given-names>Filomeen</given-names>
</name>
<address>
<email>Filomeen.Haerynck@uzgent.be</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Clinical Immunology Research Lab, Department of Pulmonary Medicine, Centre for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Centre, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Centre, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2069 7798</institution-id><institution-id institution-id-type="GRID">grid.5342.0</institution-id><institution>Center for Medical Genetics, </institution><institution>Ghent University and Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000104788040</institution-id><institution-id institution-id-type="GRID">grid.11486.3a</institution-id><institution>Laboratory of Immunoregulation, </institution><institution>VIB Inflammation Research Centre, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2069 7798</institution-id><institution-id institution-id-type="GRID">grid.5342.0</institution-id><institution>Department of Internal Medicine, </institution><institution>Ghent University, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution>Immunology Service, Department of Laboratory Medicine, NIH Clinical Centre, </institution><institution>National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Department of Ophthalmology, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution>Division of Ophthalmology, </institution><institution>The Children’s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, USA </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Department of Paediatric Cardiology, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0350 814X</institution-id><institution-id institution-id-type="GRID">grid.416084.f</institution-id><institution>Department of Paediatric Allergy and Immunology, </institution><institution>Montreal Children’s Hospital, </institution></institution-wrap>Montreal, QC Canada </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Department of Pulmonology, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>16</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>7</volume>
<elocation-id>3702</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Syndromic primary immunodeficiencies are rare genetic disorders that affect both the immune system and other organ systems. More often, the immune defect is not the major clinical problem and is sometimes only recognized after a diagnosis has been made based on extra-immunological abnormalities. Here, we report two sibling pairs with syndromic primary immunodeficiencies that exceptionally presented with a phenotype resembling early-onset common variable immunodeficiency, while extra-immunological characteristics were not apparent at that time. Additional features not typically associated with common variable immunodeficiency were diagnosed only later, including skeletal and organ anomalies and mild facial dysmorphism. Whole exome sequencing revealed <italic>KMT2A</italic>-associated Wiedemann-Steiner syndrome in one sibling pair and their mother. In the other sibling pair, targeted testing of the known disease gene for Roifman syndrome (<italic>RNU4ATAC</italic>) provided a definite diagnosis. With this study, we underline the importance of an early-stage and thorough genetic assessment in paediatric patients with a common variable immunodeficiency phenotype, to establish a conclusive diagnosis and guide patient management. In addition, this study extends the mutational and immunophenotypical spectrum of Wiedemann-Steiner and Roifman syndromes and highlights potential directions for future pathophysiological research.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>Common variable immunodeficiency (CVID) is one of the most frequently diagnosed primary immunodeficiencies (PIDs), and is defined as decreased serum immunoglobulin (Ig) G, decreased IgA and/or IgM, poor antibody responses to vaccines, and exclusion of other causes of hypogammaglobulinemia<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Patients commonly experience recurrent (sinopulmonary) infections and features of immune dysregulation such as autoimmunity<sup><xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref></sup>. About 25% of CVID patients are diagnosed in childhood<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. To rule out transient hypogammaglobulinemia of infancy, in which Ig levels spontaneously resolve mostly by the age of two to four years, a definite diagnosis of CVID should not be given before the age of four years<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>.</p>
<p>Here, we report novel familial cases of Wiedemann-Steiner syndrome (WSS) and Roifman syndrome (RS) that were initially categorized as early-onset CVID. WSS and RS are rare syndromic PIDs, affecting the immune system as well as other organ systems<sup><xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup>. Although there is considerable phenotypic heterogeneity in both syndromes, hallmark extra-immunological features are generally evident very early in life<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref></sup>. WSS is typically characterized by <italic>hypertrichosis cubiti</italic>, growth retardation, developmental delay and facial dysmorphism, and is caused by heterozygous mutations in <italic>lysine methyltransferase 2</italic> 
<italic>A</italic> (<italic>KMT2A</italic>)<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup>. <italic>KMT2A</italic> (also called <italic>mixed-lineage leukemia</italic>, <italic>MLL</italic>) encodes a histone methyltransferase involved in regulating chromatin-mediated transcription and is a frequent target of chromosomal rearrangements in childhood leukemia<sup><xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref></sup>. WSS has only been recently associated with primary antibody deficiency<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. RS, on the other hand, is commonly featured by antibody deficiency as well as growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy<sup><xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR16">16</xref></sup>. Biallelic mutations in <italic>RNU4ATAC</italic>, a noncoding small nuclear RNA (snRNA) gene, were recently identified as a cause of RS<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. U4atac snRNA is an important component of the minor spliceosome required for minor intron splicing<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
<p>This report aspires to increase awareness among immunologists and geneticists that a CVID phenotype can be the principal presentation of WSS and RS in early childhood, which is exceptional and has not been previously reported. The prior diagnosis of early-onset CVID diverted attention away from the initially less evident extra-immunological features, which significantly delayed identification of the underlying syndromic disorders. Additionally, in both families we identified mutations that have not been previously associated with disease. We aimed to provide insight as to how these mutations are disease-causing. Finally, we expand the immunophenotypical spectrum of WSS and RS, which could support future mechanistic research.</p>
</sec>
<sec id="Sec2" sec-type="results">
<title>Results</title>
<sec id="Sec3">
<title>An early-onset CVID phenotype in two unrelated sibling pairs</title>
<p>This study reports on two unrelated sibling pairs with recurrent respiratory tract infections and antibody deficiency categorized as CVID in early childhood. The family A monozygotic twin boys (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>, II:2 and II:3) were born prematurely at 34 weeks gestational age to non-consanguineous, Belgian parents and are currently 11 years old. One of them (II:3) was born with bilateral inguinal hernia and hypospadias, which were attributed to his premature birth. From the first year of life, the twin boys suffered from recurrent upper and lower respiratory tract infections, often requiring antibiotics. At 2 months of age, patient II:3 developed severe pneumonia with respiratory arrest and heart failure. The latter led to the recognition of a patent <italic>ductus arteriosus</italic>, which was surgically ligated shortly thereafter. The postoperative course was complicated by severe respiratory distress requiring ventilation and systemic corticosteroids. Upon immunological evaluation, both patients II:2 and II:3 demonstrated panhypogammaglobulinemia, poor antibody responses to Pneumococcal polysaccharide vaccine, increased naive B cells, and very low memory B cells (Table <xref ref-type="table" rid="Tab1">1</xref>). Additionally, both patients showed evidence of mild bronchiectasis on high-resolution computed tomography (HRCT) scan at 3.5 years of age.<fig id="Fig1"><label>Figure 1</label><caption><p>Family A with <italic>KMT2A</italic>-associated Wiedemann-Steiner syndrome (WSS). (<bold>a</bold>) Pedigree of family A. (<bold>b</bold>) Skipping of <italic>KMT2A</italic> exon 28. Gel electrophoresis of the <italic>KMT2A</italic> cDNA region containing exon 28 revealed a second shorter transcript in the three affected individuals. HC1 and HC2 represent two healthy controls; <italic>GAPDH</italic> was used as reference target. In-frame deletion of exon 28 was confirmed by cDNA sequencing; c.10755 and c.10835 indicate the start respectively stop position of exon 28. (<bold>c</bold>) KMT2A protein domains (adapted from ref. <xref ref-type="bibr" rid="CR9">9</xref>). KMT2A is cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which form a non-covalently associated complex. Deletion of the amino acids encoded by exon 28 may disrupt the interaction site between the two fragments.</p></caption><graphic id="d29e582" xlink:href="41598_2017_2434_Fig1_HTML"></graphic></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Routine immunological laboratory results of the family A patients with Wiedemann-Steiner syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th colspan="2">Patient II:2</th><th colspan="2">Patient II:3</th><th colspan="2">Patient I:2</th></tr><tr><th>Value</th><th>Reference range</th><th>Value</th><th>Reference range</th><th>Value</th><th>Reference range</th></tr></thead><tbody><tr><td>
<bold>White blood cells</bold>
</td><td colspan="2">
<italic>Age: 8 years</italic>
</td><td colspan="2">
<italic>Age: 8 years</italic>
</td><td colspan="2">
<italic>Age: 45 years</italic>
</td></tr><tr><td>  Total leukocytes (no./µL)</td><td>11930</td><td>6000–14000</td><td>7340</td><td>6000–14000</td><td>7210</td><td>3650–9300</td></tr><tr><td>  Neutrophils (no./µL)</td><td>6980</td><td>2000–8000</td><td>3150</td><td>2000–8000</td><td>3450</td><td>1573–6100</td></tr><tr><td>  Lymphocytes (no./µL)</td><td>3990</td><td>1500–7500</td><td>3480</td><td>1500–7500</td><td>2870</td><td>1133–3105</td></tr><tr><td>    CD3+ T cells (no./µL)</td><td>2630</td><td>700–4200</td><td>2580</td><td>700–4200</td><td>2240</td><td>700–2100</td></tr><tr><td>      CD3+ CD4+ T helper cells (no./µL)</td><td>1600</td><td>300–2000</td><td>1640</td><td>300–2000</td><td>1120</td><td>300–1400</td></tr><tr><td>        CD45RA + naive CD4 + T cells (%)</td><td>82</td><td>46–77<sup>†</sup>
</td><td>82</td><td>46–77<sup>†</sup>
</td><td>44</td><td>NA</td></tr><tr><td>        CD45RO+ memory CD4+ T cells (%)</td><td>12</td><td>13–30<sup>†</sup>
</td><td>10</td><td>13–30<sup>†</sup>
</td><td>50</td><td>NA</td></tr><tr><td>      CD3+ CD8+ T cytotoxic cells (no./µL)</td><td>838</td><td>300–1800</td><td>800</td><td>300–1800</td><td>1060</td><td>200–1200</td></tr><tr><td>        CD45RA+ naive CD8+ T cells (%)</td><td>80</td><td>63–92<sup>†</sup>
</td><td>69</td><td>63–92<sup>†</sup>
</td><td>26</td><td>NA</td></tr><tr><td>        CD45RO+ memory CD8+ T cells (%)</td><td>12</td><td>4–21<sup>†</sup>
</td><td>10</td><td>4–21<sup>†</sup>
</td><td>73</td><td>NA</td></tr><tr><td>    CD19+ B cells (no./µL)</td><td>798</td><td>200–1600</td><td>592</td><td>200–1600</td><td>287</td><td>100–500</td></tr><tr><td>      IgD + CD27- naive B cells (%)</td><td>96</td><td>47.3–77.0<sup>‡</sup>
</td><td>94</td><td>47.3–77.0<sup>‡</sup>
</td><td>88</td><td>48.4–79.7<sup>‡</sup>
</td></tr><tr><td>      CD24 + + CD38++ transitional B cells (%)</td><td>19</td><td>4.6–8.3<sup>‡</sup>
</td><td>10</td><td>4.6–8.3<sup>‡</sup>
</td><td>14</td><td>0.9–5.7<sup>‡</sup>
</td></tr><tr><td>      IgD − CD27+ switched memory B cells (%)</td><td>1</td><td>10.9–30.4<sup>‡</sup>
</td><td>1</td><td>10.9–30.4<sup>‡</sup>
</td><td>6</td><td>8.3–27.8<sup>‡</sup>
</td></tr><tr><td>      IgD + CD27+ marginal zone B cells (%)</td><td>2</td><td>5.2–20.4<sup>‡</sup>
</td><td>2</td><td>5.2–20.4<sup>‡</sup>
</td><td>3</td><td>7.0–23.8<sup>‡</sup>
</td></tr><tr><td>      CD21<sup>low</sup> CD38<sup>low</sup> B cells (%)</td><td>2</td><td>2.3–10.0<sup>‡</sup>
</td><td>3</td><td>2.3–10.0<sup>‡</sup>
</td><td>2</td><td>1.6–10.0<sup>‡</sup>
</td></tr><tr><td>    CD3 − CD56 + CD16+ NK cells (no./µL)</td><td>479</td><td>90–900</td><td>244</td><td>90–900</td><td>344</td><td>90–600</td></tr><tr><td>  Monocytes (no./µL)</td><td>690</td><td>700–1500</td><td>570</td><td>700–1500</td><td>780</td><td>247–757</td></tr><tr><td>  Eosinophils (no./µL)</td><td>220</td><td>200–500</td><td>100</td><td>200–500</td><td>80</td><td>28–273</td></tr><tr><td>  Basophils (no./µL)</td><td>30</td><td>10–100</td><td>20</td><td>10–100</td><td>10</td><td>6–50</td></tr><tr><td>
<bold>Immunoglobulins</bold>*</td><td colspan="2">
<italic>Age: 7 years</italic>
</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td colspan="2">
<italic>Age: 45 years</italic>
</td></tr><tr><td>    IgG (g/L)</td><td>3.6</td><td>4.70–10.5</td><td>2.8</td><td>4.70–9.30</td><td>7.6</td><td>7.0–16.0</td></tr><tr><td>    IgG2 (g/L)</td><td>1.13</td><td>0.85–4.10</td><td>0.54</td><td>0.63–3.0</td><td>3.03</td><td>1.50–6.40</td></tr><tr><td>    IgG3 (g/L)</td><td>0.265</td><td>0.13–1.42</td><td>0.176</td><td>0.13–1.26</td><td>0.307</td><td>0.20–1.10</td></tr><tr><td>    IgM (g/L)</td><td>&lt;0.2</td><td>0.27–0.63</td><td>&lt;0.2</td><td>0.27–0.57</td><td>&lt;0.18</td><td>0.40–2.48</td></tr><tr><td>    IgA (g/L)</td><td>0.3</td><td>0.50–1.41</td><td>0.3</td><td>0.41–0.91</td><td>2.35</td><td>0.71–3.65</td></tr><tr><td>    IgE (kU/L)</td><td>&lt;4.4</td><td>0–90</td><td>&lt;4.4</td><td>0–60</td><td>NA</td><td></td></tr><tr><td>
<bold>Specific antibody responses</bold>*</td><td colspan="2">
<italic>Age: 7 years</italic>
</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td colspan="2">
<italic>Age: 45 years</italic>
</td></tr><tr><td>    <italic>S</italic>. <italic>pneumoniae</italic> polysaccharide IgG (Lab U)</td><td>NA</td><td></td><td>9</td><td>≥11: immune</td><td>NA</td><td></td></tr><tr><td>    <italic>S</italic>. <italic>pneumoniae</italic> polysaccharide IgG: specific IgG response to 3 serotypes (8, 9 N, 15B)</td><td>Insufficient antibody response</td><td>2x titer increase for at least 2 out of 3 serotypes</td><td>NA</td><td></td><td>Good antibody response</td><td>2x titer increase for at least 2 out of 3 serotypes</td></tr><tr><td>   Tetanus IgG (IU/mL)</td><td>0.01</td><td> ≥ 0.01: immune</td><td>0.03</td><td> ≥ 0.01: immune</td><td>0.50</td><td> ≥ 0.01: immune</td></tr><tr><td>   Rubella IgG (IU/mL)</td><td>12</td><td>&gt;10: immune</td><td>44</td><td>&gt;10: immune</td><td>NA</td><td></td></tr><tr><td>   Measles IgG (mIU/mL)</td><td>350</td><td>&gt;300: immune</td><td>1200</td><td>&gt;300: immune</td><td>NA</td><td></td></tr><tr><td>   Mumps IgG (Lab U/mL)</td><td>270</td><td>&gt;500: immune</td><td>540</td><td>&gt;500: immune</td><td>NA</td><td></td></tr><tr><td>   Varicella Zoster IgG (mIU/mL)</td><td>620</td><td>&gt;100: immune</td><td>1400</td><td>&gt;100: immune</td><td>NA</td><td></td></tr><tr><td>
<bold>Lymphocyte proliferation assay</bold>
</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td></td><td></td></tr><tr><td>   Response to Concanavalin A</td><td>Normal</td><td>Compared to control</td><td>Normal</td><td>Compared to control</td><td>NA</td><td></td></tr><tr><td>   Response to Phytohemagglutinin</td><td>Normal</td><td>Compared to control</td><td>Normal</td><td>Compared to control</td><td>NA</td><td></td></tr><tr><td>   Response to Tetanus toxoid</td><td>Normal</td><td>Compared to control</td><td>Moderately reduced</td><td>Compared to control</td><td>NA</td><td></td></tr></tbody></table><table-wrap-foot><p>The most recent, comprehensive and representative laboratory results are shown for each patient. Patients II:2 and II:3 were immunized according to the recommended Belgian childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. Patient I:2 had received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal vaccine was given to patients II:2 and I:2 at time of immunological evaluation; patient I:2 had never received a pneumococcal vaccine before then. Patients II:2 and II:3 were not vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. *Measured when not receiving immunoglobulin replacement therapy. <sup>†</sup>Reference values from Shearer <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. <sup>‡</sup>Reference values from Piatosa <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p></table-wrap-foot></table-wrap>
</p>
<p>The family B brother and sister pair (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>, II:1 and II:2) were born to healthy, non-consanguineous, Belgian parents and are currently 17 and 14 years of age respectively. They had recurrent upper and lower respiratory tract infections since the age of 18 months (II:1) and 3 years (II:2). The girl (II:2) also had recurrent gastroenteritis in early childhood and diffuse atopic eczema since infancy. Similar to the family A sibling pair, they had panhypogammaglobulinemia and poor global antibody responses to Pneumococcal polysaccharide vaccine (Table <xref ref-type="table" rid="Tab2">2</xref>). Serotype-specific Pneumococcal antibody responses were not evaluated. In contrast to the family A twins, the family B siblings demonstrated severe B cell lymphopenia with normal switched memory B cell percentages and increased CD21<sup>low</sup> B cell levels (Table <xref ref-type="table" rid="Tab2">2</xref>). HRCT scan in patient II:1 at the age of 7.5 years displayed marked bronchiectasis, whereas his sister (II:2) only showed discrete bronchiectasis at a similar age.<fig id="Fig2"><label>Figure 2</label><caption><p>Family B with <italic>RNU4ATAC</italic>-associated Roifman syndrome (RS). (<bold>a</bold>) Pedigree of family B. (<bold>b</bold>) Representative retinal images of the RS patients. Panel I, composite retinal image of fundus of left eye (LE) of patient II:1: note inferior outer retinal atrophy with greyish hue and intraretinal pigment migration of the spicular type in inferior retina; mottled aspect of retinal pigment epithelium, more pronounced in inferotemporal area. Panel II, blue light autofluorescence image of LE of patient II:1 showing hyperautofluorescent delineation of inferior atrophic zone, as well as superior to optic disc, illustrating more widespread disease than can be seen on white light fundoscopic image only. Panel III, similar image of right eye (RE) of patient II:1 as in Panel II. Panel IV, fundus picture of detail of superonasal midperiphery of RE of patient II:2. Despite a normal full-field flash electroretinography, recent fundus examination at 14 years of age showed a mild mottling of pigment epithelium suggestive of early stage retinal dystrophy. (<bold>c</bold>) U4atac snRNA showing structural elements, conserved positions and location of variants associated with RS (adapted from ref. <xref ref-type="bibr" rid="CR8">8</xref>). The here-reported variant that has not been previously associated with RS is shown in red.</p></caption><graphic id="d29e1649" xlink:href="41598_2017_2434_Fig2_HTML"></graphic></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Routine immunological laboratory results of the family B patients with Roifman syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th colspan="2">Patient II:1</th><th colspan="2">Patient II:2</th></tr><tr><th>Value</th><th>Reference range</th><th>Value</th><th>Reference range</th></tr></thead><tbody><tr><td>
<bold>White blood cells</bold>
</td><td colspan="2">
<italic>Age: 14 years</italic>
</td><td colspan="2">
<italic>Age: 11 years</italic>
</td></tr><tr><td>  Total leukocyte count (no./µL)</td><td>7720</td><td>4500–12000</td><td>9800</td><td>4500–12000</td></tr><tr><td>  Neutrophils (no./µL)</td><td>5290</td><td>2500–8000</td><td>6080</td><td>2500–8000</td></tr><tr><td>  Lymphocytes (no./µL)</td><td>1190</td><td>1500–6500</td><td>2410</td><td>1500–6500</td></tr><tr><td>    CD3+ T cells (no./µL)</td><td>940</td><td>800–3500</td><td>1740</td><td>800–3500</td></tr><tr><td>      CD3 + CD4+ T helper cells (no./µL)</td><td>643</td><td>400–2100</td><td>1080</td><td>400–2100</td></tr><tr><td>        CD45RA+ naive CD4+ T cells (%)</td><td>55</td><td>33–66<sup>†</sup>
</td><td>68</td><td>33–66<sup>†</sup>
</td></tr><tr><td>        CD45RO+ memory CD4+ T cells (%)</td><td>38</td><td>18–38<sup>†</sup>
</td><td>27</td><td>18–38<sup>†</sup>
</td></tr><tr><td>      CD3 + CD8+ T cytotoxic cells (no./µL)</td><td>274</td><td>200–1200</td><td>603</td><td>200–1200</td></tr><tr><td>        CD45RA+ naive CD8+ T cells (%)</td><td>60</td><td>61–91<sup>†</sup>
</td><td>67</td><td>61–91<sup>†</sup>
</td></tr><tr><td>        CD45RO+ memory CD8+ T cells (%)</td><td>33</td><td>4–23<sup>†</sup>
</td><td>22</td><td>4–23<sup>†</sup>
</td></tr><tr><td>    CD19+ B cells (no./µL)</td><td>36</td><td>200–600</td><td>48</td><td>200–600</td></tr><tr><td>      IgD + CD27- naive B cells (%)</td><td>77</td><td>51.3–82.5<sup>‡</sup>
</td><td>70</td><td>51.3–82.5<sup>‡</sup>
</td></tr><tr><td>      CD24 + + CD38++ transitional B cells (%)</td><td>15</td><td>1.4–13.0<sup>‡</sup>
</td><td>5</td><td>1.4–13.0<sup>‡</sup>
</td></tr><tr><td>      IgD-CD27+ switched memory B cells (%)</td><td>9</td><td>8.7–25.6<sup>‡</sup>
</td><td>10</td><td>8.7–25.6<sup>‡</sup>
</td></tr><tr><td>      IgD + CD27+ marginal zone B cells (%)</td><td>4</td><td>4.6–18.2<sup>‡</sup>
</td><td>1</td><td>4.6–18.2<sup>‡</sup>
</td></tr><tr><td>      CD21<sup>low</sup> CD38<sup>low</sup> B cells (%)</td><td>22</td><td>2.7–8.7<sup>‡</sup>
</td><td>21</td><td>2.7–8.7<sup>‡</sup>
</td></tr><tr><td>    CD3-CD56 + CD16+ NK cells (no./µL)</td><td>179</td><td>70–1200</td><td>554</td><td>70–1200</td></tr><tr><td>  Monocytes (no./µL)</td><td>910</td><td>500–1000</td><td>960</td><td>500–1000</td></tr><tr><td>  Eosinophils (no./µL)</td><td>290</td><td>100–500</td><td>230</td><td>100–500</td></tr><tr><td>  Basophils (no./µL)</td><td>20</td><td>10–100</td><td>90</td><td>10–100</td></tr><tr><td>
<bold>Immunoglobulins</bold>*</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td colspan="2">
<italic>Age: 6 years</italic>
</td></tr><tr><td>   IgG (g/L)</td><td>3.8</td><td>4.7–9.3</td><td>4.4</td><td>4.7–10.5</td></tr><tr><td>   IgG2 (g/L)</td><td>0.53</td><td>0.63–3.0</td><td>0.49</td><td>0.85–4.1</td></tr><tr><td>   IgG3 (g/L)</td><td>0.021</td><td>0.13–1.26</td><td>0.242</td><td>0.13–1.42</td></tr><tr><td>   IgM (g/L)</td><td>&lt;0.2</td><td>0.27–0.57</td><td>0.3</td><td>0.27–0.63</td></tr><tr><td>   IgA (g/L)</td><td>0.3</td><td>0.41–0.91</td><td>&lt;0.3</td><td>0.5–1.41</td></tr><tr><td>  IgE (kU/L)</td><td>&lt;4.4</td><td>0–60</td><td>&lt;4.4</td><td>0–90</td></tr><tr><td>
<bold>Isohemagglutinins</bold>*</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td></td><td></td></tr><tr><td>  ABO blood type</td><td>O</td><td></td><td>NA</td><td></td></tr><tr><td>  Anti-A IgM</td><td>Negative</td><td>Positive</td><td>NA</td><td></td></tr><tr><td>  Anti-B IgM</td><td>Negative</td><td>Positive</td><td>NA</td><td></td></tr><tr><td>
<bold>Specific antibody responses</bold>*</td><td colspan="2">
<italic>Age: 3 years</italic>
</td><td colspan="2">
<italic>Age: 6 years</italic>
</td></tr><tr><td>  <italic>S</italic>. <italic>pneumoniae</italic> polysaccharide IgG (Lab U)</td><td>&lt;3</td><td> ≥ 11: immune</td><td>7</td><td> ≥ 11: immune</td></tr><tr><td>  Tetanus IgG (IU/mL)</td><td>0.03</td><td> ≥ 0.01: immune</td><td>1</td><td> ≥ 0.01: immune</td></tr><tr><td>  Rubella IgG (IU/mL)</td><td>&lt;8</td><td>&gt;10: immune</td><td>NA</td><td></td></tr><tr><td>  Measles IgG (mIU/mL)</td><td>&lt;150</td><td>&gt;300: immune</td><td>NA</td><td></td></tr><tr><td>  Mumps IgG (Lab U/mL)</td><td>&lt;230</td><td>&gt;500: immune</td><td>NA</td><td></td></tr><tr><td>  Varicella zoster IgG (mIU/mL)</td><td>360</td><td>&gt;100: immune</td><td>1400</td><td>&gt;100: immune</td></tr><tr><td>
<bold>Lymphocyte proliferation assay</bold>
</td><td colspan="2">
<italic>Age: 9 years</italic>
</td><td colspan="2">
<italic>Age: 6 years</italic>
</td></tr><tr><td>  Response to Concanavalin A</td><td>Normal</td><td>Compared to control</td><td>Normal</td><td>Compared to control</td></tr><tr><td>  Response to Phytohemagglutinin</td><td>Normal</td><td>Compared to control</td><td>Normal</td><td>Compared to control</td></tr><tr><td>  Response to Tetanus toxoid</td><td>Normal</td><td>Compared to control</td><td>Normal</td><td>Compared to control</td></tr></tbody></table><table-wrap-foot><p>The most recent, comprehensive and representative laboratory results are shown for each patient. Both patients were immunized according to the recommended Belgian childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. A polysaccharide (unconjugated) pneumococcal vaccine was given at time of immunological evaluation. The patients were not vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. *Measured when not receiving immunoglobulin replacement therapy. <sup>†</sup>Reference values from Shearer <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. <sup>‡</sup>Reference values from Piatosa <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p></table-wrap-foot></table-wrap>
</p>
<p>In both the family A and B sibling pairs, the clinical presentation and laboratory findings in the first years of life were reminiscent of a CVID phenotype. All patients are currently doing well under regular Ig replacement therapy, antiflogistic maintenance treatment with azithromycin and intermittent inhaled corticosteroids and/or short-acting beta-agonists therapy.</p>
</sec>
<sec id="Sec4">
<title>Extra-immunological features raised suspicion of syndromic PID</title>
<p>Although both sibling pairs first presented with a phenotype resembling CVID, with time they gradually demonstrated additional clinical features not typically associated with CVID (Tables <xref ref-type="table" rid="Tab3">3</xref> and <xref ref-type="table" rid="Tab4">4</xref>). The family A twin boys developed a third degree atrioventricular block for which a pacemaker was implanted at 5 (II:3) and 6.5 (II:2) years of age respectively. In the following years, the boys showed increasing evidence of mild intellectual disability. In retrospect, patient II:3 had signs of mild developmental delay during the first years of life. Both twins also demonstrated poor weight gain and growth retardation, albeit to a limited extent. Around the age of 9 years, dysmorphic facial features became more conspicuous (Table <xref ref-type="table" rid="Tab3">3</xref>). Interestingly, the twins’ mother (I:2) had congenital urogenital tract anomalies consisting of a unicornuate uterus and a unique left ovary, fallopian tube and kidney. Moreover, since childhood, she had suffered from right unilateral sensorineural hearing loss as well as recurrent sinusitis and bronchitis frequently requiring antibiotics. At that time, genetic or immunological testing had never been performed in the mother as she deemed herself to be in good general health. The twins’ older brother (II:1) and father (I:1) had an uneventful medical history.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of the family A patients with published cases of <italic>KMT2A</italic>-associated Wiedemann-Steiner syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinical features<sup>†</sup>
</th><th rowspan="2">18 published patients<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup>
</th><th colspan="3">Present study</th></tr><tr><th>Patient II:2</th><th>Patient II:3</th><th>Patient I:2</th></tr></thead><tbody><tr><td>Gender</td><td>8 M, 10 F</td><td>M</td><td>M</td><td>F</td></tr><tr><td>Age at last examination (years)</td><td>1–24</td><td>11</td><td>11</td><td>46</td></tr><tr><td>Short stature</td><td>18/18</td><td>+</td><td>+</td><td>+</td></tr><tr><td colspan="5">
<italic>Craniofacial features</italic>
</td></tr><tr><td>   Microcephaly</td><td>2/7</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Mild macrocephaly</td><td>NA</td><td>+</td><td>+</td><td>−</td></tr><tr><td> Hypertelorism, telecantus</td><td>9/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Down-slanted palpebral fissures</td><td>14/16</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Vertically narrow palpebral fissures</td><td>13/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Strabismus</td><td>4/17</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Thick eyebrows</td><td>14/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Wide nasal bridge</td><td>16/18</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Broad nasal tip</td><td>11/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Long philtrum</td><td>2/12</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Thin upper lip</td><td>6/12</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Low-set ears</td><td>2/12</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Abnormal dentition, hypodontia</td><td>5/9</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   High palate</td><td>4/8</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Micrognathia</td><td>7/11</td><td>+</td><td>+</td><td>+</td></tr><tr><td colspan="5">
<italic>Musculoskeletal features</italic>
</td></tr><tr><td>   Advanced bone age</td><td>1/16</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>   Small hands and feet</td><td>5/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Fleshy hands and feet</td><td>3/7</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Clinodactyly</td><td>8/18</td><td>−</td><td>+</td><td>+</td></tr><tr><td>   Congenital hip dysplasia</td><td>2/17</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Muscular hypotonia</td><td>9/18</td><td>−</td><td>−</td><td>−</td></tr><tr><td colspan="5">
<italic>Dermatological features</italic>
</td></tr><tr><td>   Thick hair</td><td>14/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   <italic>Hypertrichosis cubiti</italic>
</td><td>13/18</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Hypertrichosis back and/or lower limbs</td><td>16/18</td><td>−</td><td>−</td><td>−</td></tr><tr><td colspan="5">
<italic>Neurological features</italic>
</td></tr><tr><td>   Developmental or psychomotor delay</td><td>18/18</td><td>−</td><td>+</td><td>NA</td></tr><tr><td>   Intellectual disability</td><td>16/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Autism</td><td>2/12</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Aggressive behavior</td><td>4/13</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Hyperactivity</td><td>2/12</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Seizures</td><td>1/7</td><td>−</td><td>−</td><td>−</td></tr><tr><td colspan="5">
<italic>Internal organ anomalies</italic>
</td></tr><tr><td>   Cardiovascular anomalies</td><td>3/17</td><td>+</td><td>+</td><td>−</td></tr><tr><td>   Urogenital anomalies</td><td>4/17</td><td>−</td><td>+</td><td>+</td></tr><tr><td>   Intestinal anomalies</td><td>4/11</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Feeding difficulties</td><td>10/18</td><td>+</td><td>+</td><td>−</td></tr><tr><td colspan="5">
<italic>Immunodeficiency features</italic>
</td></tr><tr><td>   Antibody deficiency</td><td>1/1</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Respiratory tract infections</td><td>2/17</td><td>+</td><td>+</td><td>+</td></tr><tr><td>   Urinary tract infections</td><td>4/18</td><td>−</td><td>−</td><td>−</td></tr><tr><td>   Bronchiectasis</td><td>NA</td><td>+</td><td>+</td><td>NA</td></tr></tbody></table><table-wrap-foot><p>NA: not available. <sup>†</sup>Not all clinical features have been ascertained in all previously published patients. Adapted from Stellacci <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Comparison of the family B patients with published cases of <italic>RNU4ATAC</italic>-associated Roifman syndrome.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinical features</th><th rowspan="2">6 published patients<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>
</th><th colspan="2">Present study</th></tr><tr><th>Patient II:1</th><th>Patient II:2</th></tr></thead><tbody><tr><td>Gender</td><td>5 M, 1 F</td><td>M</td><td>F</td></tr><tr><td>Age at last examination (years)</td><td>NA</td><td>17</td><td>14</td></tr><tr><td colspan="4">
<italic>Growth retardation</italic>
</td></tr><tr><td>   Prenatal, intra-uterine growth retardation</td><td>6/6</td><td>NA</td><td>NA</td></tr><tr><td>   Postnatal growth retardation</td><td>6/6</td><td>+</td><td>+</td></tr><tr><td colspan="4">
<italic>Craniofacial features</italic>
</td></tr><tr><td>   Mild microcephaly</td><td>5/6</td><td>+</td><td>+</td></tr><tr><td>   Long philtrum</td><td>6/6</td><td>+</td><td>+</td></tr><tr><td>   Thin upper lips</td><td>6/6</td><td>+</td><td>+</td></tr><tr><td>   Narrow, tubular and upturned nose</td><td>6/6</td><td>+</td><td>+</td></tr><tr><td colspan="4">
<italic>Ophthalmological features</italic>
</td></tr><tr><td>   Retinal dystrophy</td><td>3/6</td><td>+</td><td>+</td></tr><tr><td colspan="4">
<italic>Musculoskeletal features</italic>
</td></tr><tr><td>   Epiphyseal dysplasia</td><td>6/6</td><td>+</td><td>−</td></tr><tr><td>   Vertebral changes</td><td>3/6</td><td>+</td><td>−</td></tr><tr><td>   Coxa vara</td><td>NA</td><td>+</td><td>−</td></tr><tr><td>   Agenesis of anterior cruciate ligaments</td><td>NA</td><td>+</td><td>−</td></tr><tr><td>   Agenesis of 12<sup>th</sup> ribs</td><td>NA</td><td>+</td><td>−</td></tr><tr><td>   Short metacarpals</td><td>6/6</td><td>+</td><td>−</td></tr><tr><td>   5<sup>th</sup> digit clinodactyly</td><td>4/6</td><td>−</td><td>−</td></tr><tr><td>   Brachydactyly</td><td>6/6</td><td>+</td><td>−</td></tr><tr><td>   Transverse palmar crease</td><td>5/6</td><td>−</td><td>−</td></tr><tr><td>   Muscular hypotonia</td><td>5/6</td><td>−</td><td>−</td></tr><tr><td colspan="4">
<italic>Neurological features</italic>
</td></tr><tr><td>   Intellectual disability, cognitive delay</td><td>5/6</td><td>−</td><td>−</td></tr><tr><td>   Sensorineural hearing loss</td><td>1/6</td><td>−</td><td>−</td></tr><tr><td colspan="4">
<italic>Internal organ anomalies</italic>
</td></tr><tr><td>   Noncompaction of the myocardium</td><td>1/6</td><td>−</td><td>−</td></tr><tr><td>   Ventricular septum defect (VSD)</td><td>1/6</td><td>−</td><td>−</td></tr><tr><td>   Lung hypoplasia</td><td>NA</td><td>−</td><td>+</td></tr><tr><td colspan="4">
<italic>Immunodeficiency and atopic features</italic>
</td></tr><tr><td>   Antibody deficiency</td><td>6/6</td><td>+</td><td>+</td></tr><tr><td>   Hepatosplenomegaly</td><td>5/6</td><td>−</td><td>−</td></tr><tr><td>   Bronchiectasis</td><td>NA</td><td>+</td><td>+</td></tr><tr><td>   Eczema</td><td>3/6</td><td>−</td><td>+</td></tr></tbody></table><table-wrap-foot><p>NA: not available.</p></table-wrap-foot></table-wrap>
</p>
<p>Analogously, the boy in family B (II:1) initially displayed subtle syndromic features, such as mild growth retardation, that appeared more pronounced over time. At the age of seven years, diverse skeletal abnormalities including spondyloepiphyseal dysplasia were detected (Table <xref ref-type="table" rid="Tab4">4</xref>). At the same age, he was also found to have slowly progressive retinal dystrophy (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>, Panels I-III) with decreased rod function but near-normal cone function on full-field flash electroretinography. Antibody deficiency in combination with skeletal and ophthalmological features led to the clinical suspicion of RS in the boy. However, his sister (II:2) had no radiographic sings of spondyloepiphyseal or hip dysplasia nor retinal dystrophy. Moreover, RS was originally presumed to be an X-linked recessive condition, although no causal gene had been identified<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. When the family B girl (II:2) was about 9 years old, Gray <italic>et al</italic>. reported the first female patient with RS, having a skewed X-inactivation and a milder phenotype than her affected brother<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Subsequently, we hypothesized that patient II:2 might be a manifesting heterozygote of RS, which could be compatible with her milder extra-immunological phenotype at that time.</p>
</sec>
<sec id="Sec5">
<title>Cytogenetic and cytogenomic analyses were negative in both sibling pairs</title>
<p>In the family A twins, conventional G-banding karyotype, fluorescent <italic>in situ</italic> hybridization for region 22q11.2 and subtelomeric screening were normal. Furthermore, microarray-based comparative genomic hybridisation analysis in both sibling pairs did not demonstrate copy number variations.</p>
</sec>
<sec id="Sec6">
<title>Whole exome sequencing (WES) uncovers WSS in family A</title>
<p>Since no specific genetic syndrome was suspected in family A, WES was performed in patient II:2 and both parents. This revealed a heterozygous splice site variant in <italic>KMT2A</italic> (NM_001197104:c.10835 + 1 G &gt; A), present in the twins (II:2, II:3) as well as in the mother (I:2) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). The variant is not reported in public or in-house databases. The <italic>KMT2A</italic> nucleotide substitution is situated in the splice donor site of intron 28. <italic>In silico</italic> splicing prediction tools suggested complete loss of the splice donor site resulting in exon 28 skipping and an in-frame deletion of 81 bp, which was confirmed by analyses on cDNA derived from patients’ PBMCs (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>). Mature KMT2A protein is physiologically cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which together form a non-covalently associated complex (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>)<sup><xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref></sup>. Complex formation is necessary for stability and subnuclear localization of the protein<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The amino acids encoded by exon 28 are part of the interaction site between KMT2A-N and KMT2A-C (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. It has been shown that disrupting the interaction between the two fragments causes degradation of the KMT2A-N fragment and loss of protein function<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The KMT2A-N fragment was only very weakly detectable by western blot on PBMC lysates, however, and could therefore not be reliably interpreted (data not shown). Subsequent investigations in the mother demonstrated mild intellectual disability, undetectable serum IgM, and reduced switched memory B cells (Table <xref ref-type="table" rid="Tab1">1</xref>). Taken together, the c.10835 + 1 G &gt; A variant in <italic>KMT2A</italic> indicates a molecular diagnosis of WSS in the twin brothers and their mother.</p>
</sec>
<sec id="Sec7">
<title>Targeted sequencing confirms the diagnosis of RS in family B</title>
<p>In family B, WES was unable to identify a potentially disease-causing variant. In 2015, biallelic mutations in <italic>RNU4ATAC</italic> were identified in patients with RS<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Since <italic>RNU4ATAC</italic> is a noncoding snRNA gene, possible variants would have been missed with WES. Indeed, subsequent Sanger sequencing of <italic>RNU4ATAC</italic> revealed compound heterozygous variants in both siblings (c.13 C &gt; T and c.116 A &gt; T) that segregated in the parents (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>). The c.13 C &gt; T variant (rs559979281) had been previously reported in RS (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The c.116 A &gt; T variant has, to our knowledge, not yet been associated with human disease. The public database gnomAD (Genome Aggregation Database) contains two heterozygotes for the c.116 A &gt; T variant (allele frequency of 0.00001531) but no homozygotes. Importantly, the c.116 A &gt; T variant is located in a highly conserved position involved in splicing activity (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Furthermore, position 116 is immediately adjacent to the Sm protein-binding site, which is a highly conserved structural element essential in splicing activity and previously implicated in RS (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Together, the <italic>RNU4ATAC</italic> genotype confirms the diagnosis of RS in the family B siblings.</p>
</sec>
<sec id="Sec8">
<title>Immunological abnormalities in the WSS and RS patients</title>
<p>Because of the prominent immunodeficiency in both sibling pairs, we performed flow cytometric analysis of B and T lymphocyte subsets as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Interestingly, all patients from families A and B had decreased circulating follicular helper T (cTfh) cells (Fig. <xref ref-type="fig" rid="Fig3">3a,b</xref>). Tfh cells play an essential role in the formation of antibody-producing plasma cells and memory B cells<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Furthermore, the two RS patients showed markedly reduced expression levels of B cell activating factor-receptor (BAFF-R), a receptor important in peripheral B cell survival (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. The WSS patients had normal BAFF-R levels (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>). Expression of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), a receptor related to BAFF-R, was normal in both the WSS and RS patients (Fig. <xref ref-type="fig" rid="Fig3">3a,b</xref>)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. For all patients, the alterations in naive and memory lymphocyte subsets (Supplementary Figs <xref ref-type="media" rid="MOESM1">1</xref>–<xref ref-type="media" rid="MOESM1">4</xref>) corresponded with those seen in the routine laboratory assessment (Table <xref ref-type="table" rid="Tab1">1</xref>). Other examined B and T cell populations fell within the range of the age-matched healthy controls (Supplementary Figs <xref ref-type="media" rid="MOESM1">1</xref>–<xref ref-type="media" rid="MOESM1">4</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>cTfh cells, BAFF-R expression and TACI expression in WSS and RS patients. (<bold>a</bold>) Family A patients with <italic>KMT2A</italic>-associated Wiedemann-Steiner syndrome (WSS). The twins (II:2, II:3) were 8 years old and the mother (I:2) was 43 years old at time of analysis. (<bold>b</bold>) Family B patients with <italic>RNU4ATAC</italic>-associated Roifman syndrome (RS). At time of analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. Flow cytometric immunophenotyping was performed on patients’ PBMCs in comparison with age-matched healthy controls (HC). T cells were gated as CD3<sup>+</sup> and B cells as CD19<sup>+</sup>CD20<sup>+</sup> in total PBMCs. Circulating follicular helper T (cTfh) cells were gated as CXCR5<sup>+</sup>CD45RO<sup>+</sup> in CD4<sup>+</sup> T cells. BAFF-R and TACI expression were measured on B cells. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of the HC groups represent mean ± standard deviation. BAFF-R: B cell activating factor-receptor, cTfh: circulating follicular helper T, expr: expression, TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor.</p></caption><graphic id="d29e3933" xlink:href="41598_2017_2434_Fig3_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec9" sec-type="discussion">
<title>Discussion</title>
<p>We report two sibling pairs with an early-onset CVID phenotype as primary and cardinal presentation of WSS and RS: recurrent sinopulmonary infections, panhypogammaglobulinemia, reduced polysaccharide vaccine responses, and aberrant peripheral B cell subsets<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Because extra-immunological features were initially subtle and only became conspicuous with age, the establishment of an accurate diagnosis was significantly delayed. Therefore, we recommend to proactively evaluate all paediatric patients with a CVID phenotype for extra-immunological syndromic features, especially when presenting at an early age. In particular, diagnostic workup should include evaluation by a clinical geneticist, in addition to orthopedic, cardiologic, neurologic, urogenital and ophthalmologic assessment. To reach a conclusive diagnosis, genetic testing should be performed, varying from targeted testing of a specific disease gene to WES. Here, the diagnosis of WSS in family A was only confirmed upon WES in affected family members<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref></sup>. In family B on the other hand, WES failed to reveal the causal genetic defect because this was located in a noncoding gene<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Targeted testing of the known disease gene for RS allowed to identify the underlying mutations and to provide a definite diagnosis<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Of note, if WES does not identify a genetic defect and there is no known disease gene, whole genome sequencing should be undertaken<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p>
<p>With this study, we extend the phenotypical and mutational spectrum of both <italic>KMT2A</italic>-associated WSS and <italic>RNU4ATAC</italic>-associated RS<sup><xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup>. In family A, we identified a novel heterozygous splice site mutation in <italic>KMT2A</italic> causing in-frame deletion of exon 28. This deletion likely disrupts the stabilizing interaction site between the N- and C-terminal KMT2A fragments, resulting in loss of protein function<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. So far, we were unable to confirm this on a protein level because the KMT2A-N protein fragment was not reliably detectable by western blot. Further studies on protein level are planned in the future. Family A is the first published kindred to show autosomal dominant transmission of <italic>KMT2A</italic>-associated WSS in multiple generations, as previously reported cases were either sporadic or parents were unavailable<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Remarkably, the characteristic hypertrichosis of elbows, back and/or lower limbs was absent in the here-reported WSS patients, confirming previous literature that this feature may not be as pathognomonic as initially believed<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref></sup>. Interestingly, <italic>KMT2A</italic>-associated WSS shows phenotypical overlap with Kabuki syndrome type 1 caused by heterozygous mutations in the related gene <italic>KMT2D</italic>
<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Over 80% of patients with <italic>KMT2D</italic>-associated Kabuki syndrome develop defects in terminal B cell differentiation resulting in antibody deficiency<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Similarly, the here-described WSS patients demonstrated a block in terminal B cell differentiation evidenced by a relative increase in transitional and naive B cells and a relative decrease in switched memory B cells. Moreover, they had reduced levels of cTfh cells, which play a pivotal role in terminal B cell differentiation<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Decreased cTfh cells have, to our knowledge, not been previously reported in WSS or Kabuki syndrome. It would be interesting to investigate cTfh cells in additional patients with <italic>KMT2A</italic>-associated WSS and <italic>KMT2D</italic>-associated Kabuki syndrome as this may help elucidate the underlying pathophysiology of the antibody deficiency. In summary, humoral immune deficiency in patients with WSS reported by us and by Stellacci <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and antibody deficiency in patients with heterozygous mutations in the related <italic>KMT2D</italic> gene<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, strongly suggest a previously unknown role for <italic>KMT2A</italic> in B cell biology that may be related with T helper cell function.</p>
<p>In family B, we identified rare compound heterozygous mutations in the noncoding <italic>RNU4ATAC</italic> gene, of which one mutation (c.116 A &gt; T) had not been associated with RS before<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Although it was not initially apparent, with time the boy showed typical features of RS including spondyloepiphyseal dysplasia and retinal dystrophy<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Curiously, he also demonstrated bilateral agenesis of the anterior cruciate ligaments and the 12<sup>th</sup> ribs, which are not typically seen in RS<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Spondyloepiphyseal or hip dysplasia have not yet been documented in the girl, currently 14 years old, although she displays mild growth retardation. Only recently, she was found to have mild fundus abnormalities suggestive of early stage retinal dystrophy. Note that retinal dystrophy was already evident in her brother at 7 years of age. It would be interesting to investigate why the girl has a milder phenotype than her brother. Since U4atac snRNA plays a role in minor intron splicing, it would be valuable to conduct RNA sequencing analysis in the two siblings and check for possible differences in intron retention<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Detailed immunological workup in the RS patients revealed markedly decreased BAFF-R expression on B cells. To our knowledge, this finding has not been previously published. As BAFF-R signalling is important for survival of B cells in the peripheral blood, this may provide an important clue towards the B cell lymphopenia seen in RS patients<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Moreover, analogous to the WSS patients, the RS siblings demonstrated decreased levels of cTfh cells, which may further compromise B cell differentiation and antibody production<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p>
<p>In conclusion, we here illustrate that a CVID phenotype can be the initial presentation of WSS and RS in early childhood while hallmark extra-immunological characteristics may be less prominent. With this, we highlight the importance of pursuing a genetic diagnosis in paediatric patients with an early-onset CVID phenotype, as this has important implications in terms of counselling, follow-up and screening for complications associated with the specific disorder.</p>
</sec>
<sec id="Sec10" sec-type="materials|methods">
<title>Methods</title>
<sec id="Sec11">
<title>Statement</title>
<p>All experiments and methods were carried out in accordance with relevant guidelines and regulations. The research protocol and all experimental protocols were approved by the ethical committee of Ghent University Hospital (2012/593). All reported subjects provided written informed consent for participation in the study, in accordance with the 1975 Helsinki Declaration.</p>
</sec>
<sec id="Sec12">
<title>Cytogenetic analyses</title>
<p>Microarray-based comparative genomic hybridization (array CGH) was performed on the affected sibling pairs of families A and B using the SurePrint G3 Human CGH Microarray Kit according to manufacturer’s instructions (Agilent Technologies). Results were analyzed with arrayCGHbase<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Karyotype analysis was performed on the family A twins using the conventional G-banding technique. To screen the family A twins for submicroscopic subtelomeric rearrangements, multiplex ligation-dependent probe amplification (MLPA) analysis was performed using SALSA P070 and SALSA P036C probe mixes according to manufacturer’s instructions (MRC-Holland). To examine the family A twins for 22q11.2 deletion, fluorescence <italic>in situ</italic> hybridization (FISH) analysis was performed using the DiGeorge Region Probe Set – LSI TUPLE 1 SpectrumOrange/LSI ARSA SpectrumGreen according to manufacturer’s instructions (Vyvis).</p>
</sec>
<sec id="Sec13">
<title>WES</title>
<p>Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation kit (Qiagen) according to manufacturer’s instructions. Whole exome enrichment was performed with the SureSelectXT Human All Exon V5 + UTRs kit (Agilent Technologies). Paired-end massively parallel sequencing (100 cycles) was performed on a NextSeq 500 (Illumina). Read mapping against the human genome reference sequence (NCBI, GRCh37), and post-mapping duplicate read removal, quality-based variant calling and coverage analysis were performed with CLC Genomics Workbench v6.0.4 (CLC bio). Sequencing coverage is summarized in Supplementary Table <xref ref-type="media" rid="MOESM1">S1</xref>. Called variants with coverage ≥3 were annotated with Alamut Batch (Interactive Biosoftware). Only variants with population frequencies less than 10% were considered, according to public databases NCBI dbSNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>), NHLBI Exome Sequencing Project (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), ExAC Browser (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>), and 1000 Genomes Project Browser (<ext-link ext-link-type="uri" xlink:href="http://browser.1000genomes.org/">http://browser.1000genomes.org/</ext-link>). Variants were further prioritized based on allele frequency, functional prediction scores, nucleotide conservation scores and biological relevance<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Both Mendelian and non-Mendelian inheritance patterns were taken into account. Afterwards, variants of interest were evaluated using Alamut Visual mutation interpretation software v2.7 rev. 1 (Interactive Biosoftware), Ingenuity Variant Analysis (QIAGEN, 2015 Release Spring), CADD scores v1.3 (<ext-link ext-link-type="uri" xlink:href="http://cadd.gs.washington.edu/home">http://cadd.gs.washington.edu/home</ext-link>), genome Aggregation Database (gnomAD) Browser (<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org">http://gnomad.broadinstitute.org</ext-link>), literature search, segregation analysis in available family members, and frequency in an in-house database containing variants of more than 1000 exomes at time of analysis.</p>
</sec>
<sec id="Sec14">
<title>Sanger sequencing of genomic DNA</title>
<p>DNA templates (GRCh37/hg19) of <italic>KMT2A</italic> (NM_001197104) and <italic>RNU4ATAC</italic> (NR_023343) were obtained from UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu">https://genome.ucsc.edu</ext-link>). Primers for amplification and sequencing were designed with Primer3Plus<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. For <italic>KMT2A</italic> exon 28 and adjacent intron-exon borders (family A): forward primer 5′-CAACCCACAAGGGTGTCTTC-3′ and reverse primer 5′-GCCCGGCTAATTCTTTTTGT-3′. For the unique exon and intron-exon borders of <italic>RNU4ATAC</italic> (family B): forward primer 5′-TGGAGGCTGGAGGTAAGCTA-3′ and reverse primer 5′-TGAGGTGCAAAGACCTACTGAA-3′. Genomic DNA was amplified by PCR using the specific primers and KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically purified with Exonuclease I and Antartic phosphatase (both New England BioLabs Inc.). Purified PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqScape v2.5 (ThermoFisher Scientific).</p>
</sec>
<sec id="Sec15">
<title>RNA extraction, cDNA synthesis and confirmation of skipping of exon 28 in <italic>KMT2A</italic></title>
<p>Total RNA was isolated from total PBMCs of all family A members and two control subjects by use of the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), according to manufacturer’s instructions. The cDNA template (GRCh37/hg19) of <italic>KMT2A</italic> (NM_001197104) was obtained from UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu">https://genome.ucsc.edu</ext-link>). Primers for amplification and sequencing of exon 28 and adjacent coding regions were designed with Primer3Plus<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>: forward primer 5′-AACCCAAACCAAAAACCAAAC-3′ and reverse primer 5′-CATCAGTGGGGAGCTGAAAT-3′. <italic>GAPDH</italic> was used as a reference target: forward primer 5′-CAGCCTCAAGATCATCAGCA-3′ and reverse primer 5′-TGTGGTCATGAGTCCTTCCA-3′. PCR amplification was performed by use of GoTaq Hot Start Colorless Master Mix (Promega). PCR products were analyzed on a 2% agarose gel in 1x TBE buffer (Quality Biological Inc). SYBR Safe (Invitrogen) signals were captured with a Gel Doc EZ Imager system (Bio-Rad). In addition, purified PCR products were Sanger sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3130xL Genetic Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqMan (DNAStar).</p>
</sec>
<sec id="Sec16">
<title>Flow cytometric analysis of PBMCs</title>
<p>Immunophenotyping was performed on PBMCs of patients and age-matched healthy controls. PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient centrifugation and cryopreserved at −150 °C. Thawed PBMCs were stained with fixable viability dye 506 (eBioscience) and fluorescently labeled monoclonal antibodies under saturation conditions as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Cells were acquired on an LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed with FlowJo version X (Tree Star Inc.).</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec17">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2017_2434_MOESM1_ESM.pdf"><caption><p>Supplementary information</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>Elfride De Baere and Filomeen Haerynck contributed equally to this work.</p>
</fn>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>
<bold>Supplementary information</bold> accompanies this paper at doi:10.1038/s41598-017-02434-4
</p>
</fn>
<fn>
<p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>The authors gratefully acknowledge the families who participated in this study. This study was supported by the Ghent University Hospital Spearhead Initiative for Immunology Research, the Jeffrey Modell Foundation to F.H., the Research Foundation Flanders (FWO) to D.B., B.P.L, F.C., B.N.L. and E.D.B., the Ghent University Special Research Fund (BOF15/GOA/011) to E.D.B., Hercules foundation AUGE/13/023 to E.D.B., a European Research Council consolidator grant to B.N.L., an Interuniversity Attraction Pole grant to B.N.L., the University of Ghent MRP program “Group-ID” to B.N.L., and the NIH Clinical Center intramural research program to H.S.K., J.E.N. and S.D.R. D.B. is a PhD fellow, F.C. a postdoctoral fellow, and E.D.B. and B.P.L. are Senior Clinical Investigators of the FWO.</p>
</ack>
<notes notes-type="author-contribution">
<title>Author Contributions</title>
<p>D.J.B. performed the genetic analyses, the experiments and data analysis, and drafted the initial manuscript. M.D., H.S.K. and S.D.R. supervised experiments and data analysis, and critically reviewed and revised the manuscript. J.E.N. assisted in protein structure analysis and critically reviewed and revised the manuscript. B.P.L., H.D.W., S.D.S., B.N.L. and F.D.B. managed patients, provided clinical data and critically reviewed and revised the manuscript. M.D.B. and F.C. assisted in genetic analyses and critically reviewed and revised the manuscript. E.D.B. supervised genetic analyses and critically reviewed and revised the manuscript. F.H. conceptualized the study, managed patients, provided and interpreted clinical data, and critically reviewed and revised the manuscript. All authors provided critical input and approved the final manuscript as submitted.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Competing Interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonilla</surname>
<given-names>FA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International Consensus Document (ICON): Common Variable Immunodeficiency Disorders</article-title>
<source/>J. Allergy Clin. Immunol. Pract
          <year>2016</year>
<volume>4</volume>
<fpage>38</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaip.2015.07.025</pub-id>
<pub-id pub-id-type="pmid">26563668</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogaert</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genes associated with common variable immunodeficiency: one diagnosis to rule them all?</article-title>
<source/>J. Med. Genet.
          <year>2016</year>
<volume>53</volume>
<fpage>575</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103690</pub-id>
<pub-id pub-id-type="pmid">27250108</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resnick</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Moshier</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Godbold</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Cunningham-Rundles</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Morbidity and mortality in common variable immune deficiency over 4 decades</article-title>
<source/>Blood
          <year>2012</year>
<volume>119</volume>
<fpage>1650</fpage>
<lpage>1657</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2011-09-377945</pub-id>
<pub-id pub-id-type="pmid">22180439</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ming</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Stiehm</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>JM</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Syndromic immunodeficiencies: genetic syndromes associated with immune abnormalities</article-title>
<source/>Crit. Rev. Clin. Lab. Sci.
          <year>2003</year>
<volume>40</volume>
<fpage>587</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1080/714037692</pub-id>
<pub-id pub-id-type="pmid">14708957</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kersseboom</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weemaes</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Educational paper: syndromic forms of primary immunodeficiency</article-title>
<source/>Eur. J. Pediatr.
          <year>2011</year>
<volume>170</volume>
<fpage>295</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-011-1396-7</pub-id>
<pub-id pub-id-type="pmid">21337117</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<mixed-citation publication-type="other">Ming, J. E. &amp; Stiehm, E. R. Genetic syndromic immunodeficiencies with antibody defects. <italic>Immunol</italic>. <italic>Allergy Clin</italic>. <italic>North</italic>. <italic>Am</italic>. <bold>28</bold>, 715–736, vii, doi:10.1016/j.iac.2008.06.007 (2008).</mixed-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stellacci</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Congenital immunodeficiency in an individual with Wiedemann-Steiner syndrome due to a novel missense mutation in KMT2A</article-title>
<source/>Am. J. Med. Genet. A
          <year>2016</year>
<volume>170</volume>
<fpage>2389</fpage>
<lpage>2393</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.37681</pub-id>
<pub-id pub-id-type="pmid">27320412</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merico</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>8718</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms9718</pub-id>
<pub-id pub-id-type="pmid">26522830</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>WD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in MLL cause Wiedemann-Steiner syndrome</article-title>
<source/>Am. J. Hum. Genet.
          <year>2012</year>
<volume>91</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.06.008</pub-id>
<pub-id pub-id-type="pmid">22795537</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendelsohn</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Pronold</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smaoui</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Slavotinek</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Advanced bone age in a girl with Wiedemann-Steiner syndrome and an exonic deletion in KMT2A (MLL)</article-title>
<source/>Am. J. Hum. Genet. A
          <year>2014</year>
<volume>164a</volume>
<fpage>2079</fpage>
<lpage>2083</lpage>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strom</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De Novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing</article-title>
<source/>BMC Med. Genet.
          <year>2014</year>
<volume>15</volume>
<fpage>49</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-15-49</pub-id>
<pub-id pub-id-type="pmid">24886118</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvel</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A Case of Wiedemann-Steiner Syndrome Associated with a 46, XY Disorder of Sexual Development and Gonadal Dysgenesis</article-title>
<source/>Sex. Dev.
          <year>2015</year>
<volume>9</volume>
<fpage>289</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1159/000441512</pub-id>
<pub-id pub-id-type="pmid">26544196</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunkerton</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A de novo Mutation in KMT2A (MLL) in monozygotic twins with Wiedemann-Steiner syndrome</article-title>
<source/>Am. J. Med. Genet. A
          <year>2015</year>
<volume>167a</volume>
<fpage>2182</fpage>
<lpage>2187</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.37130</pub-id>
<pub-id pub-id-type="pmid">25929198</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyake</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Delineation of clinical features in Wiedemann-Steiner syndrome caused by KMT2A mutations</article-title>
<source/>Clin. Genet.
          <year>2016</year>
<volume>89</volume>
<fpage>115</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12586</pub-id>
<pub-id pub-id-type="pmid">25810209</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yokoyama</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kitabayashi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ayton</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ohki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties</article-title>
<source/>Blood
          <year>2002</year>
<volume>100</volume>
<fpage>3710</fpage>
<lpage>3718</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2002-04-1015</pub-id>
<pub-id pub-id-type="pmid">12393701</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roifman</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Antibody deficiency, growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy: a novel syndrome</article-title>
<source/>Clin. Genet.
          <year>1999</year>
<volume>55</volume>
<fpage>103</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1034/j.1399-0004.1999.550206.x</pub-id>
<pub-id pub-id-type="pmid">10189087</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Sillence</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kakakios</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Is Roifman syndrome an X-linked ciliopathy with humoral immunodeficiency? Evidence from 2 new cases</article-title>
<source/>Int. J. Immunogenet.
          <year>2011</year>
<volume>38</volume>
<fpage>501</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.1111/j.1744-313X.2011.01041.x</pub-id>
<pub-id pub-id-type="pmid">21977988</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Erdjument-Bromage</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tempst</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Korsmeyer</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization</article-title>
<source/>Mol. Cell. Biol.
          <year>2003</year>
<volume>23</volume>
<fpage>186</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.23.1.186-194.2003</pub-id>
<pub-id pub-id-type="pmid">12482972</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogaert</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The immunophenotypical fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives</article-title>
<source/>Haematologica
          <year>2017</year>
<volume>102</volume>
<fpage>192</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2016.149112</pub-id>
<pub-id pub-id-type="pmid">27634199</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Nurieva</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Transcriptional regulation of follicular T-helper (Tfh) cells</article-title>
<source/>Immunol. Rev.
          <year>2013</year>
<volume>252</volume>
<fpage>139</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1111/imr.12040</pub-id>
<pub-id pub-id-type="pmid">23405901</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rickert</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Jellusova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miletic</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease</article-title>
<source/>Immun. Rev
          <year>2011</year>
<volume>244</volume>
<fpage>115</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01067.x</pub-id>
<pub-id pub-id-type="pmid">22017435</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meienberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bruggmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Oexle</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matyas</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Clinical sequencing: is WGS the better WES?</article-title>
<source/>Hum. Genet.
          <year>2016</year>
<volume>135</volume>
<fpage>359</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-015-1631-9</pub-id>
<pub-id pub-id-type="pmid">26742503</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<mixed-citation publication-type="other">Lindsley, A. W. <italic>et al</italic>. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. <italic>J</italic>. <italic>Allergy Clin</italic>. <italic>Immunol</italic>. <bold>137</bold>, 179–187.e110, doi:10.1016/j.jaci.2015.06.002 (2016).</mixed-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menten</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays</article-title>
<source/>BMC bioinformatics
          <year>2005</year>
<volume>6</volume>
<fpage>124</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-6-124</pub-id>
<pub-id pub-id-type="pmid">15910681</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppieters</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identity-by-descent-guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy</article-title>
<source/>Genet. Med.
          <year>2014</year>
<volume>16</volume>
<fpage>671</fpage>
<lpage>680</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2014.24</pub-id>
<pub-id pub-id-type="pmid">24625443</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Untergasser</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Primer3Plus, an enhanced web interface to Primer3</article-title>
<source/>Nucleic Acids Res
          <year>2007</year>
<volume>35</volume>
<fpage>W71</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkm306</pub-id>
<pub-id pub-id-type="pmid">17485472</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shearer</surname>
<given-names>WT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study</article-title>
<source/>J. Allergy Clin. Immunol.
          <year>2003</year>
<volume>112</volume>
<fpage>973</fpage>
<lpage>980</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2003.07.003</pub-id>
<pub-id pub-id-type="pmid">14610491</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piatosa</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood</article-title>
<source/>Cytometry B Clin. Cytom
          <year>2010</year>
<volume>78</volume>
<fpage>372</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.1002/cyto.b.20536</pub-id>
<pub-id pub-id-type="pmid">20533385</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>